Scope of the work
Kevin’s Ultragenyx remit included electronic clinical outcome assessment and electronic patient-reported outcome capabilities supporting Phase II–III research and Phase IV programs. He founded and mentored the Innovation Lab to assess whether a requirement should be met through an external product, an internal application, or a combination of capabilities.
His experience joins endpoint and protocol discussions to the operational detail of patient and site data capture. It includes product ownership, requirements, vendor governance, development oversight, quality, validation, training, support, and continuing improvement.
Connecting an endpoint to a usable workflow
The relevant design work began with the clinical need and the intended users. Kevin served on protocol development teams where technology feasibility, endpoint strategy, patient burden, site practice, and operational risk had to be considered together. His organization translated those requirements into data-capture experiences and the associated support model.
A survey is only one part of that system. The participant must receive the right request, understand what to report, have a workable device and connection, and know where to obtain help. The site and study team must be able to recognize missing information and distinguish a data problem from a workflow problem. These are the operating concerns his platform and service-delivery work addressed.
Sourcing and development leadership
Kevin led vendor evaluation and governance while also building an internal alternative. This gave his team responsibility for examining functional fit, implementation effort, the quality system, integration needs, support obligations, and the total operational burden of a solution. His role included mentoring others in the analysis rather than keeping every decision at department-head level.
For internally developed applications, the organization provided product, engineering, QA/CSV, informatics, and service delivery. For external capabilities, Kevin coordinated expectations with regulated technology partners and internal quality and study stakeholders.
Relevant delivery evidence
Rarify is the principal platform example. It brought patient- and site-reported information into a collaborative clinical environment, alongside metabolic monitoring and connected-device data. The Innovation Lab supported validation and release readiness, and extended service delivery to training, participant/site support, and device logistics.
The evidence establishes leadership of eCOA/ePRO technology selection and execution. It should not be interpreted as a claim that Kevin personally developed every clinical instrument, performed psychometric validation, or served as the statistical authority for the endpoints.
Why this experience transfers
Electronic outcome-assessment programs need someone who can connect clinical purpose, product choices, vendor obligations, and real-world participation. Kevin has led the organization performing that work and has managed its financial, technical, and service dimensions. The combination is particularly relevant when a sponsor is establishing a new function, reviewing its vendor model, or introducing data collection that crosses patient, site, and device boundaries.
Sources and record basis
The project account is based on Kevin’s CV, approved career statements, and supporting project materials. Related public research and professional work are available in the source index.